Asafetida

Quick links to important sections

Asafetida

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Asafetida

Property Description
Active Identity Oleo-gum-resin (containing Organosulfides)
Primary Form Powder (also Tincture, Capsules)
Pharmacological Class Traditional Herbal Medicine, Carminative Agent
Common Use (General) Relief of gaseous tension and bloating
Origin Western Asia (Ferula assa-foetida)

Defining the Source and Identity

Asafetida (Asafoetida) is a natural, plant-derived oleo-gum-resin exudate that holds the classification of a Traditional Herbal Medicine. This complex substance is sourced from the dried sap obtained from the roots of the perennial herb Ferula assa-foetida, native to Western Asia (Iran and Afghanistan). The identity of this substance is clinically recognized for its traditional actions, and its fluid extract is acknowledged as a substance generally regarded as safe (GRAS) for specific food uses.


Composition and Classification: Is Asafetida a Phytomedicine?

Asafetida is a Phytomedicine defined by its intricate composition, rather than a single active compound, and is therefore without an International Nonproprietary Name (INN). Chemically, its distinguishing feature is the presence of significant volatile oil rich in unique organosulfides. Pharmacological studies have supported the anti-flatulent properties and suggested the potential for smooth muscle tissue relaxation in the digestive system. The crude material is processed into a fine, aromatic powder or a liquid tincture, classifying it as a Galenical preparation suitable for oral ingestion as a single botanical drug.


General Purpose: What is Asafetida Traditionally Used For?

The general purpose of Asafetida is to function as a high-level digestive aid and carminative agent. This traditional use is linked to the action of its volatile components on the gastrointestinal tract. Asafetida is employed to help relieve uncomfortable feelings of bloating, abdominal tension, and excess gas by supporting the body's natural processes of gas expulsion. Research into the anti-spasmodic properties of Ferula compounds indicates their potential to reduce digestive muscle contractions.

Regulatory References

  1. FDA GRAS Status for Asafetida

What side effects are possible with Asafetida?

Possible side effects and safety information

The safety profile for Asafetida, a traditional oleo-gum-resin, is structured around documented adverse reactions and strict population-specific restrictions as established in official regulatory summaries. Frequency classifications for most effects are Not Defined in standard regulatory documents.


System-Organ-Class Adverse Reactions

Adverse reactions reported in official literature are grouped into several systems:

  • Gastrointestinal Disorders: The most commonly reported issues involve the digestive tract, including diarrhea, nausea, vomiting, intestinal gas, burping, and stomach irritation.
  • Nervous System Disorders: Possible adverse effects include headache, dizziness, and the potential for Convulsions (seizures), which is noted as a serious adverse reaction.
  • Vascular/Hematological Disorders: Safety information indicates a potential to interfere with blood pressure control, leading to high or low blood pressure, and an increased risk of bleeding or hemorrhage. Severe Blood Disorders like methemoglobinemia have been specifically documented in infants.

Population-Specific Safety Constraints

The substance is Contraindicated for use in several high-risk populations, based on documented safety concerns:

  • Infants: Use is UNSAFE due to the specific risk of severe blood disorders (methemoglobinemia).
  • Pregnancy and Breastfeeding: Use must be avoided due to documented concerns of potential abortifacient activity and the risk of adverse effects passing to the nursing infant.
  • Pre-existing Conditions: Individuals with Bleeding Disorders or a history of Epilepsy or Convulsions are officially restricted from use due to the potential to aggravate these conditions.

Safety-Related Restrictions

Official safety guidance mandates that use should be discontinued at least two weeks prior to any scheduled surgical procedure due to documented concerns about slowed blood clotting. The safety framework is defined by the absolute necessity to restrict usage in vulnerable populations, framing the risk understanding around the potential for serious, low-frequency events.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding overexposure to the oleo-gum-resin Asafetida is primarily derived from high-level regulatory directives found in official government labeling. As a Traditional Herbal Medicine, the official documentation does not detail a specific clinical toxicology profile or a comprehensive set of symptoms for acute overdose, unlike synthetic medicinal products.

Official Regulatory Guidance for Overdose

The official guidance emphasizes immediate external support in the event of suspected overexposure. The regulatory text dictates two primary actions that must be taken:

  • Seek Medical Help: The instruction is to get medical help immediately following any known or suspected accidental overconsumption.
  • Contact Poison Control: It is officially mandated to contact a Poison Control Center right away for specialized guidance on managing overexposure.
Overdose Component Regulatory Status in Official Labeling
Documented Clinical Symptoms No specific clinical signs, symptoms, or laboratory findings for acute overdose are detailed.
Specific Antidote No specific antidote is documented or known.
Supportive Procedures No specific supportive procedures or monitoring requirements are outlined.

Urgent medical attention is required whenever an overdose is known or suspected. The regulatory framework for Asafetida focuses entirely on initiating this immediate contact with emergency services rather than relying on a complex assessment of symptoms.

Therapeutic Uses of Asafetida

The core therapeutic application of Asafetida is commonly used across domains where additional symptomatic support is needed. This traditional remedy is relevant in clinical settings marked by increased discomfort or tension, helping to address groups of symptoms that may appear suddenly or fluctuate.

Managing Gaseous Disturbance and Functional Cramping

Asafetida is commonly applied in clinical contexts marked by heightened patient distress from gaseous disturbance and intestinal spasms, such as symptoms of Irritable Bowel Syndrome (IBS). It is relevant in situations involving recurrent or episodic manifestations of functional gastrointestinal disorders, along with general stomach cramping and painful abdominal distension. This usage may offer supportive relief that helps ease the overall symptom burden of these involuntary muscular symptoms, and may assist with maintaining functional stability during periods of heightened symptoms.

It is considered relevant in contexts involving traditional respiratory support, including spasmodic cough and chest congestion.


Quick Fact: Symptomatic Relief Domains
Primary Focus: Symptoms related to physical discomfort from flatulence and bloating (Gaseous Disturbance).
Symptom Category: Applied in conditions characterized by periods of heightened symptoms related to organ-specific functional stress.

Regulatory References

  1. U.S. Food and Drug Administration (FDA) regulatory listing

Eligibility and Restrictions for Use

Asafetida's official eligibility profile is strictly defined by regulatory warnings that limit its use to adults who do not possess specific contraindications. Use is absolutely prohibited in several population groups due to documented health risks.

Population Regulatory Status Basis for Exclusion
Infants & Children Contraindicated Risk of methemoglobinemia (a severe blood disorder).
Pregnant Women Contraindicated Risk of miscarriage due to abortifacient properties.
Lactating Women Contraindicated Risk of passing constituents into breast milk, potentially causing infant blood disorders.

The product is further contraindicated for any individual with existing comorbidities that may be negatively impacted by the substance. This includes patients with a known history of bleeding disorders, as the substance may slow blood clotting. Individuals with epilepsy or other seizure disorders, as well as those with uncontrolled blood pressure (high or low), must not use Asafetida. A standard contraindication applies to those with a known allergy or hypersensitivity to Asafetida or members of the Apiaceae plant family. Any adult scheduled for surgery must discontinue use at least two weeks prior to the procedure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory interaction profile for Asafetida (Ferula assa-foetida), a substance classified as a Traditional Herbal Medicine, is defined by the absence of specific, formally documented interaction statements in government-issued labeling.

Interaction Scope and Mechanisms

Major government regulatory documents, including those from the U.S. Food and Drug Administration (FDA) and European national authorities, do not formally list any specific drug–drug interactions for Asafetida. No medicinal product categories or individual medicines are formally identified as interacting agents.

Consequently, the regulatory profile contains no documented statements regarding explicit pharmacokinetic mechanisms, such as CYP enzyme inhibition or induction, or transporter-mediated interactions (e.g., P-gp effects). Furthermore, no pharmacodynamic interactions, such as additive effects with other substance classes, are formally described in regulatory documents.

Administration Restrictions and High-Level Classification

The regulatory status does not mandate any timing-based interaction rules, spacing requirements, or restrictions on co-administration with other drugs. No combinations are formally classified as contraindicated due to interaction risk in official prescribing information. The FDA classifies Asafetida Gum and Fluid Extract as Generally Recognized As Safe (GRAS) for specific uses in food, which is a statement of food safety and does not impose interaction restrictions for medicinal co-administration.

Overall Profile

The official regulatory profile is characterized by the absence of specific, label-mandated constraints that define interacting substances or procedural requirements related to co-administration.

Mechanism of Action

How Asafetida Works: Mechanism of Action

Asafetida's action is defined by a multi-target mechanism focused on smooth muscle, inflammatory pathways, and glandular secretion. Key components modulate smooth muscle tone by functioning as functional antagonists at muscarinic cholinergic receptors and histamine H1 receptors, while acting as a stimulant on beta-adrenoceptors. This receptor interaction reduces intracellular calcium levels, leading to smooth muscle relaxation in the gastrointestinal and respiratory tracts.

Simultaneously, the drug engages cellular defense mechanisms. It acts as an inhibitor of Cyclooxygenase (COX) enzymes and modulates the expression of inflammatory signaling molecules. Activation of the Nrf2 pathway increases the expression of endogenous antioxidant enzymes, resulting in a decrease in pro-inflammatory mediator synthesis and an alteration in redox signaling. Furthermore, its components stimulate secretory glands, resulting in increased output of saliva, bile, and digestive enzymes, which facilitates the chemical breakdown of nutrients.

Dosage and Administration Information

Asafetida (Ferula assa-foetida L.) is regulated primarily as a Generally Recognized as Safe (GRAS) flavoring agent in food rather than a pharmaceutical drug with a standard drug label. The official instructions for its use are structured by its food additive status and documented traditional practices.

Official Administration Guidelines

Administration Scope Regulatory Statements
Route of Administration Oral (intended for consumption in food or traditional preparations).
Official Dosage Form Recognized forms for regulated products include the Fluid Extract and Gum (Oleoresin).
Dosing Schedule Traditionally, a daily dosage of the resin 200 to 500 mg is noted for systematic intake, although clinical dosing is not supported by robust data.
Age-Group Administration The substance is considered UNSAFE for infants and is advised to be avoided during pregnancy and breastfeeding.

Procedural Structure

Official regulations define the use of Asafetida as a Flavor Enhancer (Technical Effect), meaning it must be administered by the oral route as a food component. This framework dictates that proper use involves its incorporation into food products in its approved forms. The primary administration constraint, as noted in authoritative sources, is the avoidance of use in certain vulnerable populations.

Connection to the Overall Use Protocol

Official regulatory documentation classifies Asafetida by its use-context constraint as a food additive, which guides its application in commercial food production. For non-food use, the administration protocol adheres to traditional oral consumption, with dosage information often referencing historical ranges compiled by non-regulatory bodies, but with strict precautions against use in infants and pregnant individuals to ensure proper use safety.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Asafetida


Evidence for use in Digestive Discomfort (Functional Dyspepsia and Bloating)

Research has explored the potential of Asafetida in the context of functional digestive issues, particularly functional dyspepsia (non-ulcer indigestion) and general symptoms of gaseous discomfort and bloating. The studies primarily involve a small number of short-term randomized, placebo-controlled clinical trials (RCTs). These trials included adult populations and focused on outcomes related to physical discomfort. Researchers examined how patient-reported outcomes for symptoms such as bloating and postprandial fullness change over time using validated symptom scales.

The findings describe patterns observed in the studies over the short follow-up periods, typically around 30 days. These studies report how symptoms evolved in the observed populations when compared to a placebo. Reported outcomes were short-term and based on small populations, and the evidence is limited, which means findings provide only preliminary insight into these outcomes related to systemic or functional imbalance.

Study Focus: Bloating, Flatulence, and Antispasmodic Activity

Evidence related to the primary purpose of Asafetida as a carminative agent is largely derived from traditional medical literature and preclinical studies (lab and animal research). These studies explored the potential for the substance to promote smooth muscle relaxation in the digestive tract. Clinical data specifically for isolated symptoms of gaseous discomfort are often limited, with information frequently extrapolated from the broader functional dyspepsia trials. The evidence contributes to understanding symptom patterns, but certainty is limited given the nature of the small-scale studies.


Evidence for use in Respiratory Function (Asthma)

Asafetida was studied for its application in conditions associated with acute or disruptive episodes, specifically in the context of stable severe asthma. Research has explored the use of the substance through a limited number of short-term, randomized, placebo-controlled clinical trials in a narrow population of adults. Researchers examined outcomes related to daily functioning using specific asthma control test scores, as well as outcomes reflecting daily functioning or activity level (such as PFTs).

The evidence is still limited and data are still emerging regarding the research into this specific indication, as findings were specific to the small populations studied and the short duration of the intervention (typically 30 days).


Long-Term Studies and Follow-up Durations

The available research provides context but not individual predictions regarding the long-term effects of Asafetida. The follow-up durations for most clinical trials are limited, usually lasting 30 days or less. This means that long-term effects are not fully established, and there is limited information for long-term outcomes. Research has yet to explore follow-up outcomes over several months or years in a controlled setting.

Key Studies & References

  1. Evaluation of antispasmodic property of $Ferula$ $assa$-$foetida$: an in vitro study on isolated rat ileum
  2. Safety of $Ferula$ $assa$-$foetida$ in traditional Iranian medicine: a narrative review

Frequently Asked Questions (FAQ)

Common questions about Asafetida (FAQ)

Q: Is Asafetida the same thing as Hing?

A: Yes, the substance Asafetida is widely known by the common name Hing, particularly in South Asia and traditional contexts. Official-adjacent sources and product descriptions often use these names interchangeably when discussing the plant gum-resin.


Q: Does Asafetida have any official government safety classifications?

A: Yes, in the United States, the Food and Drug Administration (FDA) classifies Asafetida as Generally Recognized as Safe (GRAS). This classification applies specifically to its documented use as a flavoring agent or ingredient in food products.


Q: Is Asafetida considered a dietary supplement or a medicine in official documents?

A: Official U.S. regulations define the substance primarily by its use as a Generally Recognized as Safe (GRAS) flavoring agent. While this is not a medicinal classification, it may also be found listed as an active ingredient in some over-the-counter or homeopathic preparations.


Q: Why is Asafetida sometimes referred to as 'food of the gods' or 'devil's dung'?

A: The substance has acquired contrasting historical names due to its unique characteristics. It is sometimes called 'devil’s dung' because of the strong, sulfurous odor imparted by its volatile compounds. Conversely, it is known as 'food of the gods' due to its perceived value in traditional applications.


Q: Is a garlic or onion taste in the mouth normal after using Asafetida?

A: The characteristic odor and taste are sometimes perceived as a residual effect. The substance contains sulfur-containing chemical compounds, similar to those in garlic, which can lead to gastrointestinal side effects such as burping or gas, resulting in this taste.


Q: Can people with high blood pressure generally use Asafetida?

A: Official safety information notes that the substance is restricted for individuals with high or low blood pressure conditions. This restriction is noted because the substance has the potential to interfere with the body’s natural blood pressure control mechanisms.


Q: Is there a distinction in official documents between Asafetida resin and tincture?

A: Regulatory documents recognize the Gum (Oleoresin) and the Fluid Extract as standardized forms of the substance. A tincture is generally a preparation made by dissolving the resin in alcohol, which may align with the description of a Fluid Extract in some contexts.


Q: What active components in Asafetida are currently being studied?

A: Research has identified the key chemical components of the gum-resin that are the subject of study. These include several types of sulfur-containing compounds, as well as the plant compounds ferulic acid, umbelliferone, and various sesquiterpene coumarins.


Q: Are there different forms of Asafetida (e.g., powder, capsule, oil)?

A: Official documents focus on the Gum (Oleoresin) and Fluid Extract as regulated forms. However, the substance is widely available in commercial markets in various other preparations, including fine powders (often mixed with fillers), capsules, and essential oils.


Q: Is the use of Asafetida in infants a common research topic?

A: Official safety warnings provide specific restrictions regarding its use in this population. Authoritative medical sources advise that the substance is considered unsafe for infants due to the specific documented risk of severe blood disorders, such as methemoglobinemia.


Q: How is the strength of Asafetida products typically standardized?

A: Official standards, such as those in pharmacopeias, define quality and strength requirements for the oleo-gum-resin. Standardization is often based on the content of the active part of the resin, specifically requiring a minimum percentage of alcohol-soluble constituents.


Q: Why does Asafetida sometimes have a strong smell?

A: The intense and pungent smell of Asafetida originates from the volatile sulfur-containing compounds naturally present in the oleo-gum-resin. These chemicals, which include various disulfides, are responsible for its powerful aroma.


Q: What is the source of the plant used to make Asafetida?

A: The substance is an oleo-gum-resin that is obtained from the roots and stems of the Ferula assa-foetida plant. This plant is native to the arid regions of Central Asia, including countries like Iran and Afghanistan.


Q: Are there official guidelines regarding the purity of Asafetida products?

A: Yes, official quality standards, often found in pharmacopeias, define purity requirements for the resin. These standards typically specify the minimum content of the effective components and limit the amount of impurities, such as maximum ash residue.


Q: Is Asafetida generally gluten-free, based on its source materials?

A: The raw gum-resin from the plant is naturally not derived from grains. However, the substance is most commonly sold as a powdered product that is frequently compounded with inert fillers, such as rice flour or wheat flour.


Q: What is the difference between pure Asafetida and compound Hing?

A: Pure Asafetida refers to the raw oleo-gum-resin collected from the plant. Compounded Hing is a commercial product that is processed into a fine powder by blending the pure resin with carrier agents, such as cereal flours, to improve handling and reduce its intense concentration.


Q: What are the known components of Asafetida resin?

A: Chemical analysis shows that the gum-resin is a complex natural mixture. It is primarily composed of the non-volatile resin (containing components like ferulic acid and coumarins), the water-soluble gum (carbohydrates), and a powerful volatile oil (which contains the sulfur compounds).

How should Asafetida be stored and disposed of?

How to Store and Dispose of Asafetida

Asafetida is a volatile oleo-gum-resin, and its official storage is guided by the need to contain its potent odor and preserve its volatile components. The product must be stored in an air-tight container to prevent the escape of odor, maintain its composition, and protect it from moisture and air exposure.

Regulatory Storage and Disposal Rules

Requirement Description
Container Rule Store in an air-tight container to preserve volatile components.
Child Safety Keep out of the sight and reach of children.
Disposal Method Dispose of unused product according to local regulations and utilize authorized drug take-back programs where available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Asafetida found in:

A-Z Index: